Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 7% – Should You Sell?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded down 7% on Monday . The stock traded as low as $18.34 and last traded at $18.58. 72,167 shares traded hands during mid-day trading, a decline of 70% from the average session volume of 241,564 shares. The stock had previously closed at $19.99.

Analysts Set New Price Targets

DNTH has been the subject of a number of research analyst reports. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Guggenheim reiterated a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $54.33.

Dianthus Therapeutics Stock Up 3.5 %

The company has a 50 day simple moving average of $21.78 and a two-hundred day simple moving average of $24.09. The company has a market capitalization of $559.62 million, a P/E ratio of -6.97 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. As a group, research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently bought and sold shares of DNTH. R Squared Ltd bought a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $26,000. KLP Kapitalforvaltning AS bought a new stake in Dianthus Therapeutics during the 4th quarter valued at about $33,000. KBC Group NV purchased a new stake in Dianthus Therapeutics in the 4th quarter valued at about $35,000. BNP Paribas Financial Markets purchased a new stake in Dianthus Therapeutics in the 4th quarter valued at about $59,000. Finally, AlphaQuest LLC grew its stake in Dianthus Therapeutics by 273.1% in the 4th quarter. AlphaQuest LLC now owns 4,197 shares of the company’s stock worth $91,000 after acquiring an additional 3,072 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.